drugset
drugset / Trial / NCT05631327

A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors

NCT05631327 ↗

Phase 1 Terminated 12 enrolled Jazz Pharmaceuticals
Non-randomizedSequentialOpen-labelTreatment

Summary

This study will assess the safety and efficacy of JZP341 in participants with advanced or metastatic solid tumors.

Timeline

Start
2022-12-19
Primary completion
2024-04-24
Completion
2024-04-24

Outcome

Outcome not reported

Stopped (Business): “The study was terminated based on a business decision by the Sponsor.”

Drugs

EvaluationDrugModalityDoseRoute
Subject JZP341 Unknown — Intravenous

Indications

metastatic neoplasm neoplasm